Finance

Beta
Lists
INO:NASDAQ
Inovio Pharmaceuticals Inc
1,12 $
0,00%
(0,00) 1D
1,13 $
+0,89% (+0,0100)
After hours
Closed: 17 հլս, 16:00:01 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for INO...
Open
1,13 $
High
1,15 $
Low
1,10 $
Mkt. cap
92,15 մլն
Avg. vol.
1,49 մլն
Volume
829,49 հզր
52-wk high
2,98 $
52-wk low
1,03 $
EPS
-1,70 $
Beta
1,48
Shares outstanding
82,27 մլն
No. of employees
112
Open
1,13 $
High
1,15 $
Low
1,10 $
Mkt. cap
92,15 մլն
Avg. vol.
1,49 մլն
Volume
829,49 հզր
52-wk high
2,98 $
52-wk low
1,03 $
EPS
-1,70 $
Beta
1,48
Shares outstanding
82,27 մլն
No. of employees
112
News stories
From sources across the web
Profile
Inovio Pharmaceuticals, Inc. is an American biotechnology company focused on the discovery, development, and commercialization of synthetic DNA products for treating cancers and infectious diseases. In April 2020, Inovio was among some 100 companies, academic centers, or research organizations developing a vaccine candidate for treating people infected with COVID-19, with more than 170 total vaccine candidates in development. Wikipedia
About Inovio Pharmaceuticals Inc
CEOJacqueline Shea
Employees112
Founded1999
Headquarters-
Sector-
Websiteinovio.com
Analyst ratings
Based on 2 analysts giving stock ratings to INO in the past 3 months
Buy
Buy
1
Hold
1
Sell
0
12-month forecast
Based on 2 Wall Street analysts offering 12 month price targets for INO in the last 3 months.
Highest
Current 1,12 $
6,00 $ (+435,71%)
Average
4,25 $ (+279,46%)
Lowest
2,50 $ (+123,21%)
Analyst
Recommendation
Action
Price target
Projected
Date
Ram Selvaraju
H.C. Wainwright
Hold
Reiterated
2,50 $
+123,2%
06/01/2026
Edward Tenthoff
Piper Sandler
Buy
Reiterated
6,00 $
+435,7%
05/22/2026
Hartaj Singh
Oppenheimer
Buy
Maintained
13,00 $
+1 060,7%
11/11/2025
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
2025 թ. հնս
2025 թ. սեպ
2025 թ. դեկ
2026 թ. մրտ
Revenue
-
-
-
-
Cost of goods sold
14,52 մլն
13,33 մլն
10,26 մլն
14,07 մլն
Cost of revenue
14,52 մլն
13,33 մլն
10,26 մլն
14,07 մլն
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
8,56 մլն
7,88 մլն
7,22 մլն
7,88 մլն
Operating expense
8,56 մլն
7,88 մլն
7,22 մլն
7,88 մլն
Total operating expenses
23,08 մլն
21,21 մլն
17,48 մլն
21,95 մլն
Operating income
-23,08 մլն
-21,21 մլն
-17,48 մլն
-21,95 մլն
Other non operating income
-1,87 մլն
-24,27 մլն
21,17 մլն
4,14 մլն
EBT including unusual items
-23,52 մլն
-45,50 մլն
3,76 մլն
-19,68 մլն
EBT excluding unusual items
-23,57 մլն
-45,52 մլն
3,75 մլն
-19,48 մլն
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-23,52 մլն
-45,50 մլն
3,76 մլն
-19,68 մլն
Net profit margin
-
-
-
-
Earnings per share
-0,61
-0,87
-0,28
-0,31
Interest and investment income
610,64 հզր
552,11 հզր
449,34 հզր
439,59 հզր
Interest expense
-
-
-
-
Net interest expenses
610,64 հզր
552,11 հզր
449,34 հզր
439,59 հզր
Depreciation and amortization charges
-
-
-
-
EBITDA
-22,73 մլն
-20,86 մլն
-17,14 մլն
-21,63 մլն
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer